EYPT News and Press, EyePoint Pharmaceuticals Inc. From 03/08/22

Blue Sky potential due to potential blockbuster candidates with a differentiated mechanism of action. Ocular is working to leverage its proprietary technology platform to optimize drug delivery for additional eye diseases. In the second half of the year, the important data release...

WATERTOWN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced the appointment of Isabelle...

EyePoint Pharmaceuticals, Inc. (EYPT Q4 2021 Earnings Conference Call March 3, 2022, 08:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President & CEO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Geo...

Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%.&#x...

EyePoint Pharmaceuticals press release (NASDAQ:EYPT): Q4 GAAP EPS of -$0.59 misses by $0.03. Revenue of $11.54M (+61.9% Y/Y) beats by $1.75M. For further details see: EyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75M

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile seen at six-month readout – Phase 2 trials for EYP-1901 in wet AMD...

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open. The consensus EPS Estimate is -$0.51 and the consensus Revenue Estimate is $9.79M (+37.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions an...

ABUS, ARGX, ASPS, ATRS, BBY, BF.B, BIG, BILI, BJ, BURL, CAN, CNCE, CNQ, CNSL, CPG, CRH, OTCQX:DLAKF, EYPT, GLYC, GOGO, GRAB, HTOO, KR, MBT, MCS, MEI, OTCPK:MKGAF, MTLS, OXSQ, REE, REV, SBSW, OTCPK:SNCAF, SOHO, SRLP, STXS, SUP, TD, TGLS, TTC, TTSH, TWI, TZOO, UONE, UTZ, WB, WHF, WVE For Seekin...

WATERTOWN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Nancy Lurker, Chief Executi...

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call an...